These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 18467737)

  • 1. Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer?
    Nabhan C
    J Clin Oncol; 2008 May; 26(14):2413-4; author reply 2414-5. PubMed ID: 18467737
    [No Abstract]   [Full Text] [Related]  

  • 2. Re-induction of hormone sensitivity to diethylstilboestrol in androgen refractory prostate cancer patients following chemotherapy.
    Cox RA; Sundar S
    Br J Cancer; 2008 Jan; 98(1):238-9. PubMed ID: 18182981
    [No Abstract]   [Full Text] [Related]  

  • 3. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM; Ryan CW; Garzotto M; Wersinger EM; Beer TM
    J Urol; 2005 Sep; 174(3):888-92. PubMed ID: 16093981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
    Sweeney CJ
    Clin Adv Hematol Oncol; 2006 Aug; 4(8):588-90. PubMed ID: 17111557
    [No Abstract]   [Full Text] [Related]  

  • 5. [Chemotherapy for prostate cancer].
    Itoh N
    Nihon Rinsho; 2005 Feb; 63(2):293-7. PubMed ID: 15714981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.
    Beer TM; Garzotto M; Henner WD; Eilers KM; Wersinger EM
    Br J Cancer; 2004 Oct; 91(8):1425-7. PubMed ID: 15467765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
    Yuasa T
    Int J Urol; 2009 Sep; 16(9):731-2. PubMed ID: 19769657
    [No Abstract]   [Full Text] [Related]  

  • 8. Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
    Petrylak DP; Macarthur R; O'Connor J; Shelton G; Weitzman A; Judge T; England-Owen C; Zuech N; Pfaff C; Newhouse J; Bagiella E; Hetjan D; Sawczuk I; Benson M; Olsson C
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):28-33. PubMed ID: 10604266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R; Petrylak D; Agus D; Webb I; Roth B
    Clin Cancer Res; 2007 Feb; 13(4):1208-15. PubMed ID: 17317831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined treatment of metastatic hormone-resistant prostate cancer].
    Kaprin AD; Gafanov RA; Al'bitskiĭ IA; Fastovets SV
    Vopr Onkol; 2009; 55(4):477-9. PubMed ID: 19947375
    [No Abstract]   [Full Text] [Related]  

  • 11. [Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
    Wolff JM
    Onkologie; 2003 Dec; 26 Suppl 7():37-40. PubMed ID: 14716141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
    Perry CJ; Sundar S
    Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
    [No Abstract]   [Full Text] [Related]  

  • 13. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
    Savarese D; Taplin ME; Halabi S; Hars V; Kreis W; Vogelzang N
    Semin Oncol; 1999 Oct; 26(5 Suppl 17):39-44. PubMed ID: 10604268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
    Yasufuku T; Shigemura K; Matsumoto O; Arakawa S; Fujisawa M
    J Infect Chemother; 2010 Jun; 16(3):200-5. PubMed ID: 20221782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
    Nayyar R; Sharma N; Gupta NP
    Int J Urol; 2009 Sep; 16(9):726-31. PubMed ID: 19769656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
    Stadler WM; Michaelis LC; Ratain MJ
    J Clin Oncol; 2005 Nov; 23(31):8124-5; author reply 8125-6. PubMed ID: 16258115
    [No Abstract]   [Full Text] [Related]  

  • 17. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
    Oh WK; Halabi S; Kelly WK; Werner C; Godley PA; Vogelzang NJ; Small EJ;
    Cancer; 2003 Dec; 98(12):2592-8. PubMed ID: 14669278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comment to P. J. Olbert et al., page 164].
    Heidenreich A
    Aktuelle Urol; 2009 May; 40(3):169-70. PubMed ID: 19479669
    [No Abstract]   [Full Text] [Related]  

  • 20. Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
    Nakabayashi M; Sartor O; Jacobus S; Regan MM; McKearn D; Ross RW; Kantoff PW; Taplin ME; Oh WK
    BJU Int; 2008 Feb; 101(3):308-12. PubMed ID: 18184327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.